Evaluation of the Irinotecan/Bevacizumab Association as Neo-adjuvant and Adjuvant Treatment of Chemoradiation With Temozolomide for Naive Unresectable Glioblastoma. Phase II Randomized Study With Comparison to Chemoradiation With Temozolomide.
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2015
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms TemAvIr
- 29 May 2015 Time to health-related quality of life deterioration results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 01 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 24 Sep 2012 Lead trial centre changed from Federation Nationale des Centres de Lutte Contre le Cancer to UNICANCER as reported by ClinicalTrials.gov.